Table 1

 Estimated risk equations for the risk of a first primary event (equation 1), the odds of that event being fatal (equation 2) and the risk of a further primary event in the first year after a first non-fatal event (equation 3)

Explanatory baseline characteristicsEquation 1: Risk of first primary event (1069 events)*Equation 2: Odds that first event is fatal (400 events)Equation 3: Risk of subsequent event in first year after initial non-fatal event
Hazard ratioLower 95% limitUpper 95% limitOdds ratioLower 95% limitUpper 95% limitHazard ratioLower 95% limitUpper 95% limit
BMI, body mass index; MI, myocardial infarction.
*Primary trial end point of cardiovascular mortality, MI or cardiac arrest.
†Any of stroke, transient ischaemic attack or peripheral vascular disease.
‡Canadian Cardiovascular Society Angina Scale21 levels 2–4, higher level relates to worse symptoms.
Use of perindopril0.810.710.91
Age1.041.031.05
Years older than age 651.061.041.08
Male1.541.281.87
Smoker1.491.271.74
Previous MI1.441.261.661.601.192.14
Previous revascularisation0.880.770.99
Existing vascular disease†1.691.441.98
Diabetes mellitus1.491.281.74
Family history of coronary artery disease1.211.051.38
Symptomatic angina‡ or history of heart failure1.321.161.511.851.292.64
Systolic blood pressure1.001.001.01
Units creatinine clearance below 80 ml/min1.011.001.02
BMI > 30 (obese)1.411.221.63
Total cholesterol1.131.071.201.211.081.35
Using nitrates at baseline1.421.251.63
Using calcium channel blockers at baseline1.201.061.36
Using lipid-lowering treatment at baseline0.860.750.97
Constant term (on the log scale)−12.27−12.97−11.57−4.37−5.54−3.20−6.46−7.25−5.67
Ancillary parameter0.700.590.82